Roquefort Therapeutics plc (LON:ROQ) Insider Stephen Paul West Acquires 400,000 Shares

Roquefort Therapeutics plc (LON:ROQ) insider Stephen Paul West bought 400,000 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were acquired at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($14,977.53).

Roquefort Therapeutics Price Performance

Shares of ROQ stock opened at GBX 2.74 ($0.03) on Wednesday. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The stock has a 50 day moving average price of GBX 4.03 and a 200 day moving average price of GBX 4.01. Roquefort Therapeutics plc has a 52-week low of GBX 2.30 ($0.03) and a 52-week high of GBX 9.50 ($0.12). The firm has a market capitalization of £3.54 million, a P/E ratio of -274.00 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.